Back in February, the FDA approved the first cell therapy for solid tumors — Iovance Biotherapeutics’ Amtagvi (lifileucel). Amtagvi is an autologous T-cell therapy — or more specifically, a tumor-infiltrating lymphocyte (TIL) therapy (the first TIL therapy to be approved by the FDA) — for patients with previously treated, unresectable or metastatic melanoma. Learn what sets TILs apart from its other T-cell therapy counterparts and about Iovance’s preparation leading up to this monumental approval.
